SCHEMBL4030719

SCHEMBL4030719

Cc1oc(-c2ccco2)nc1COc1ccc(COc2ncccc2C=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.42
PPARG P37231 12/20 0.41
PPARA Q07869 11/20 0.41
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 3/20 0.36
RAB9A P51151 3/20 0.36
HSD17B10 Q99714 3/20 0.36
TP53 P04637 2/20 0.36
TSHR P16473 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030069 0.86 PPARG (0.55) PPARGPPARAKDM4EALDH1A1MAPT
SCHEMBL4034230 0.86 FFAR1 (0.58) FFAR1PPARGPPARAPTPN2PTPN1
SCHEMBL4031542 0.84 FFAR1 (0.43) FFAR1PPARGPPARAKDM4ENPC1
SCHEMBL4034756 0.83 KDM4E (0.43) FFAR1PPARGPPARAKDM4ENPC1
SCHEMBL5374488 0.83 FFAR1 (0.39) FFAR1PPARGPPARAKDM4ENPC1
SCHEMBL4042286 0.83 FFAR1 (0.48) FFAR1PPARGPPARAMAPTTP53
SCHEMBL4844075 0.82 PPARG (0.45) FFAR1PPARGPPARAKDM4EALDH1A1
SCHEMBL4035434 0.82 KDM4E (0.40) FFAR1PPARGPPARAKDM4ENPC1
SCHEMBL4851874 0.81 FFAR1 (0.41) FFAR1PPARGPPARAPTPN2PTPN1
SCHEMBL4029092 0.81 FFAR1 (0.45) FFAR1PPARGPPARAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357115-B1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-06-17 EP disclosed
US-7238716-B2 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2007-07-03 US disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
EP-1357115-A1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK FFAR1 4/4885PPARG 593/4885PPARA 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.